The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Still a role for chemoimmunotherapy in CLL: GREEN results
Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, discusses the final results from the phase IIIb GREEN study (NCT01905943) of obinutuzumab alone or combined with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL) . Efficacy outcomes suggest a favorable benefit/risk profile and no new safety signals were identified. Prof. Stilgenbauer reveals that in IGHV-mutated patients and in the absence of high-risk genomic features there is still a role for chemoimmunotherapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
